Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Original Article

Type and cause of liver disease in Korea: single-center experience, 2005-2010

Clinical and molecular hepatology 2012;18(3):309-315.
Published online: September 25, 2012

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

Corresponding author: Sook-Hyang Jeong. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 464-707, Korea. Tel. +82-31-787-7039, Fax. +82-31-787-4052, jsh@snubh.org

*These two authors equally contributed to this work.

• Received: June 7, 2012   • Revised: August 15, 2012   • Accepted: August 16, 2012

Copyright © 2012 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 12,684 Views
  • 106 Download
  • 51 Crossref
  • 42 Scopus
prev next

Citations

Citations to this article as recorded by  Crossref logo
  • 15-Year Long-Term Follow-Up on the Progression to Liver Cancer in a Patient with Alcoholic Hepatitis Who Continued Drinking: A Case Report and Clinical Approach
    Nahyun Cho, Hye-ri Bae, Nam-hun Lee
    The Journal of Internal Korean Medicine.2024; 45(4): 823.     CrossRef
  • Classification and Epidemiologic Aspects of Acute-on-Chronic Liver Failure
    Zaid H. Tafesh, Raquel Olivo Salcedo, Nikolaos T. Pyrsopoulos
    Clinics in Liver Disease.2023; 27(3): 553.     CrossRef
  • Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study
    Jae-Hyun Yoon, Sung-Eun Kim, Su-Hyeon Cho, Gi-Ae Kim, Yewan Park, Ji-Won Park, Seong-Hee Kang, Young-Sun Lee, Jeong-Han Kim
    Medicina.2023; 59(8): 1436.     CrossRef
  • Pharmacological Benefits and Underlying Mechanisms of Salvia miltiorrhiza against Molecular Pathology of Various Liver Diseases: A Review
    Cho Hyun Hwang, Eungyeong Jang, Jang-Hoon Lee
    The American Journal of Chinese Medicine.2023; 51(07): 1675.     CrossRef
  • Diagnosis of Cystic Hepatic Lesions on Ultrasonography
    Eun Jeong Choi, Jun Sik Yoon
    Clinical Ultrasound.2023; 8(2): 59.     CrossRef
  • Gall Bladder Stones Formation in Patients with Breast Cancer on Tamoxifen Therapy in Iraqi Female
    Israa Jarjees Rasheed Saeed, Ali Mohsin Hasan
    Open Access Macedonian Journal of Medical Sciences.2022; 10(B): 517.     CrossRef
  • Comparison of Risk Factors for Cholangiocarcinoma and Hepatocellular Carcinoma: A Prospective Cohort Study in Korean Adults
    In Rae Cho, Sang-Wook Yi, Ja Sung Choi, Jee-Jeon Yi
    Cancers.2022; 14(7): 1709.     CrossRef
  • Cost-effectiveness of chronic hepatitis C screening and treatment
    Hye Won Lee, Hankil Lee, Beom Kyung Kim, Young Chang, Jae Young Jang, Do Young Kim
    Clinical and Molecular Hepatology.2022; 28(2): 164.     CrossRef
  • Epidemiology of liver failure in Asia‐Pacific region
    Ankur Jindal, Shiv K. Sarin
    Liver International.2022; 42(9): 2093.     CrossRef
  • Which vendor is most cited in the hepatic imaging literature?
    Roya Rezvani Habibabadi, Joseph H. Huntley, Rozita Jalilianhasanpour, David M. Yousem
    Clinical Imaging.2021; 71: 39.     CrossRef
  • Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
    Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
    The Korean Journal of Internal Medicine.2021; 36(Suppl 1): S1.     CrossRef
  • Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission
    Shiv K Sarin, Manoj Kumar, Mohammed Eslam, Jacob George, Mamun Al Mahtab, Sheikh M Fazle Akbar, Jidong Jia, Qiuju Tian, Rakesh Aggarwal, David H Muljono, Masao Omata, Yoshihiko Ooka, Kwang-Hyub Han, Hye Won Lee, Wasim Jafri, Amna S Butt, Chern H Chong, Se
    The Lancet Gastroenterology & Hepatology.2020; 5(2): 167.     CrossRef
  • Bile duct ligation of C57BL/6 mice as a model of hepatic encephalopathy
    Inja Cho, Bon-Nyeo Koo, Eun Hee Kam, Su Kyoung Lee, Hanseul Oh, So Yeon Kim
    Anesthesia and Pain Medicine.2020; 15(1): 19.     CrossRef
  • Feasibility of computed tomography texture analysis of hepatic fibrosis using dual-energy spectral detector computed tomography
    ByukGyung Choi, In Young Choi, Sang Hoon Cha, Suk Keu Yeom, Hwan Hoon Chung, Seung Hwa Lee, Jaehyung Cha, Ju-Han Lee
    Japanese Journal of Radiology.2020; 38(12): 1179.     CrossRef
  • Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
    Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
    Gut and Liver.2020; 14(6): 775.     CrossRef
  • Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea
    Sang Soo Lee, Cha Young Kim, Bo Ra Kim, Ra Ri Cha, Wan Soo Kim, Jin Joo Kim, Jae Min Lee, Hong Jun Kim, Chang Yoon Ha, Hyun Jin Kim, Tae Hyo Kim, Woon Tae Jung, Ok‐Jae Lee
    Journal of Viral Hepatitis.2019; 26(4): 459.     CrossRef
  • The roles of transmembrane 6 superfamily member 2 rs58542926 polymorphism in chronic liver disease: A meta‐analysis of 24,147 subjects
    Xinpei Chen, Pengcheng Zhou, Luo De, Bo Li, Song Su
    Molecular Genetics & Genomic Medicine.2019;[Epub]     CrossRef
  • Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test
    Eun Sun Jang, Kyung‐Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook‐Hyang Jeong
    Journal of Medical Virology.2019; 91(12): 2158.     CrossRef
  • Harmful algal blooms and liver diseases: focusing on the areas near the four major rivers in South Korea
    Seungjun Lee, Jinnam Kim, Boseung Choi, Gijung Kim, Jiyoung Lee
    Journal of Environmental Science and Health, Part C.2019; 37(4): 356.     CrossRef
  • Analysis of HCV RNA Genotypes and Quantitative Values of Korean HCV NAT Reactive Blood Donors
    Sunmi Shin, Jae-won Kang, Jungwon Kang, Young Ik Seo, Jung Ran Park, Dae Dong Lee, Hyukki Min, Myunghan Kim
    The Korean Journal of Blood Transfusion.2019; 30(3): 205.     CrossRef
  • Cost-effectiveness of scaling up of hepatitis C screening and treatment: a modelling study in South Korea
    Jungyeon Kim, Markus Haacker, Salmaan Keshavjee, Rifat Atun
    BMJ Global Health.2019; 4(3): e001441.     CrossRef
  • DETECTION OF TUMOR NECROSIS FACTOR- (TNF- ) GENE PROMOTERS POLYMORPHISM AMONG LIVER CIRRHOSIS PATIENTS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN SURABAYA, INDONESIA
    Citrawati Dyah Kencono Wungu, Mochamad Amin, S. Eriaty N. Ruslan, Priyo Budi Purwono, Ulfa Kholili, Ummi Maimunah, Poernomo Boedi Setiawan, Maria Inge Lusida, Soetjipto Soetjipto, Retno Handajani
    Indonesian Journal of Tropical and Infectious Disease.2019; 7(5): 115.     CrossRef
  • Hepatic iron overload in the portal tract predicts poor survival in hepatocellular carcinoma after curative resection
    Jung Wha Chung, Eun Shin, Haeryoung Kim, Ho‐Seong Han, Jai Young Cho, Young Rok Choi, Sukho Hong, Eun Sun Jang, Jin‐Wook Kim, Sook‐Hyang Jeong
    Liver International.2018; 38(5): 903.     CrossRef
  • Recognition criteria for occupational cancers in relation to hepatitis B virus and hepatitis C virus in Korea
    Hogil Kim, Yun Kyung Chung, Inah Kim
    Annals of Occupational and Environmental Medicine.2018;[Epub]     CrossRef
  • Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea
    Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2018; 24(1): 10.     CrossRef
  • Epidemiology of alcoholic liver disease in Korea
    Jae Young Jang, Dong Joon Kim
    Clinical and Molecular Hepatology.2018; 24(2): 93.     CrossRef
  • Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents
    Jinmin Jung, Jae Hyun Kwon, Gi-Won Song, Eun-Young Tak, Vavara A. Kirchner, Sung-Gyu Lee
    Journal of Gastrointestinal Surgery.2018; 22(8): 1334.     CrossRef
  • Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea
    Sang‐Wook Yi, Ja‐Sung Choi, Jee‐Jeon Yi, Yong‐ho Lee, Ki Jun Han
    Cancer.2018; 124(13): 2748.     CrossRef
  • Seropositivity of Hepatitis C Virus among Persons affected Leprosy in Korea
    Jong-Pill Kim, Kuk-Hyeong Kang, Jin-Mo Park
    Korean Leprosy Bulletin.2018; 51(1): 13.     CrossRef
  • Outcome analysis of hip or knee arthroplasty in patients with cirrhotic liver disease
    Young-Jun Seol, Taek-Rim Yoon, Dong-Hyun Lee, Sun-Ho Lee, Kyung-Soon Park
    Journal of Orthopaedics.2017; 14(1): 171.     CrossRef
  • Clinical features of hepatitis B and C virus infections, with high α-fetoprotein levels but not hepatocellular carcinoma
    Cha Young Kim, Bo Ra Kim, Sang Soo Lee, Dae-Hong Jeon, Chang Min Lee, Wan Soo Kim, Hyun Chin Cho, Jin Joo Kim, Jae Min Lee, Hong Jun Kim, Chang Yoon Ha, Hyun Jin Kim, Tae Hyo Kim, Woon Tae Jung, Ok-Jae Lee
    Medicine.2017; 96(2): e5844.     CrossRef
  • Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea
    Bo Hyun Kim, Hwa Young Choi, Moran Ki, Kyung-Ah Kim, Eun Sun Jang, Sook-Hyang Jeong, Ming-Lung Yu
    PLOS ONE.2017; 12(8): e0182391.     CrossRef
  • Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial
    Abbaszadeh Sepideh, Parastouei Karim, Afshari Hossein, Rostami Leila, Mahmoudi Hamdollah, Ghamarchehreh Mohammad E, Sepandi Mojtaba, Samadi Mohammad, Ghanizadeh Ghader, Alavian Seyed Moayed
    Journal of the American College of Nutrition.2016; 35(6): 500.     CrossRef
  • The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
    Jeong Han Kim, Sung Hyun Ahn, Soon Young Ko, Won Hyeok Choe, Kyun-Hwan Kim, So Young Kwon
    Clinical and Molecular Hepatology.2016; 22(2): 241.     CrossRef
  • Economic Burden of Hepatitis in South Korea
    Hugh Watson, Pascal Minini, Jeffrey Encinas
    Japanese Journal of Infectious Diseases.2016; 69(4): 354.     CrossRef
  • Illness Experience of Patients with Chronic Hepatitis C Participating in Clinical Trials
    Hoo-Jeung Cho, Euna Park
    Osong Public Health and Research Perspectives.2016; 7(6): 394.     CrossRef
  • Recent outbreaks of hepatitis C virus infection in Korea and strategy for prevention
    In Hee Kim
    Journal of the Korean Medical Association.2016; 59(12): 912.     CrossRef
  • Recent outbreaks of hepatitis C virus infection in Korea and strategy for prevention
    In Hee Kim
    Journal of the Korean Medical Association.2016; 59(12): 912.     CrossRef
  • Prospective cohort study on the outcomes of hepatitis C virus‐related cirrhosis in South Korea
    Sang Soo Lee, Sook‐Hyang Jeong, Eun Sun Jang, Young Seok Kim, Youn Jae Lee, Eun Uk Jung, In Hee Kim, Si Hyun Bae, Han Chu Lee, Mee‐Kyung Kee, Chun Kang
    Journal of Gastroenterology and Hepatology.2015; 30(8): 1281.     CrossRef
  • New direct-acting antivirals for the treatment of chronic hepatitis C
    Sook-Hyang Jeong
    Journal of the Korean Medical Association.2015; 58(12): 1154.     CrossRef
  • Health Screening among HBV Carriers in the Korean National Health and Nutrition Examination Survey V (KNHANES V)
    Hyung Eun Son, Sun Jae Jung, Aesun Shin
    Asian Pacific Journal of Cancer Prevention.2015; 16(9): 3653.     CrossRef
  • Epidemiology of Hepatitis C Virus Infection in Korea
    Sook-Hyang Jeong
    Korean Journal of Medicine.2015; 88(6): 630.     CrossRef
  • Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors
    Jeong-Yeop Song, Yun Nah Lee, Young Seok Kim, Sang Gyune Kim, Soo Ji Jin, Jung Mi Park, Gyu Seong Choi, Jun Chul Chung, Min Hee Lee, Youn Hee Cho, Moon Han Choi, Dong Choon Kim, Hyun Jong Choi, Jong Ho Moon, Se Hwan Lee, Seung Won Jeong, Jae Young Jang, H
    Nuclear Medicine Communications.2015; 36(4): 319.     CrossRef
  • Factors associated with significant liver fibrosis assessed using transient elastography in general population
    Seng Chan You
    World Journal of Gastroenterology.2015; 21(4): 1158.     CrossRef
  • Clinical Features and Risk Factors for Severe Complications among Patients with Acute Hepatitis A Virus Infection in The Jeonbuk Province of Korea
    Sun Ho Yoo, In Hee Kim, Ji Won Jang, Chung Hwan Choi, Jin Chang Moon, Jin Kyoung Park, Sang Youn Lee, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon Kim, Eun Young Cho, Gum Mo Jung
    The Korean Journal of Gastroenterology.2014; 63(1): 25.     CrossRef
  • Cirrhosis and end-stage chronic liver disease: The changing scenes on etiopathogenesis
    Nabeen C. Nayak
    Current Medicine Research and Practice.2014; 4(2): 62.     CrossRef
  • Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
    Jeong Han Kim, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon
    Clinical and Molecular Hepatology.2014; 20(3): 274.     CrossRef
  • Epigenetic Mechanisms Underlying the Link between Non-Alcoholic Fatty Liver Diseases and Nutrition
    Joo Lee, Simonetta Friso, Sang-Woon Choi
    Nutrients.2014; 6(8): 3303.     CrossRef
  • The refit model for end-stage liver disease-Na is not a better predictor of mortality than the refit model for end-stage liver disease in patients with cirrhosis and ascites
    Jun Jae Kim, Jeong Han Kim, Ja Kyung Koo, Yun Jung Choi, Soon Young Ko, Won Hyeok Choe, So Young Kwon
    Clinical and Molecular Hepatology.2014; 20(1): 47.     CrossRef
  • Anti-oxidant and natural killer cell activity of Korean red ginseng (Panax ginseng) and urushiol (Rhus vernicifera Stokes) on non-alcoholic fatty liver disease of rat
    So Hyung Hong, Ki Tae Suk, Sang Hyeon Choi, Jung Wook Lee, Ho Taik Sung, Chang Hoon Kim, Eun Ji Kim, Myoung Jo Kim, Sang Hak Han, Moon Young Kim, Soon Koo Baik, Dong Joon Kim, Gyoung-Ja Lee, Sang-kyu Lee, Seung Ha Park, Ohk Hyun Ryu
    Food and Chemical Toxicology.2013; 55: 586.     CrossRef
  • HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data
    Jeong Han Kim, Yun Jung Choi, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon
    Clinical and Molecular Hepatology.2013; 19(4): 409.     CrossRef

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Type and cause of liver disease in Korea: single-center experience, 2005-2010
Korean J Hepatol. 2012;18(3):309-315.   Published online September 25, 2012
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Type and cause of liver disease in Korea: single-center experience, 2005-2010
Korean J Hepatol. 2012;18(3):309-315.   Published online September 25, 2012
Close

Figure

  • 0
  • 1
  • 2
  • 3
Type and cause of liver disease in Korea: single-center experience, 2005-2010
Image Image Image Image
Figure 1 The prevalence of liver disease types. Chronic hepatitis was the most common type of liver disease in this cohort, comprising 62.7% of the liver diseases, followed by liver cirrhosis (12.2%), acute hepatitis (8.4%), primary liver cancer (8.1%), other benign disease (8.1%), and metastatic liver cancer (0.6%).
Figure 2 Overall causes of chronic liver disease. The viral cause of chronic liver disease progressively increased from chronic hepatitis to cirrhosis, and finally to hepatocellular carcinoma (HCC; 51.2%, 73.4%, and 86.6%, respectively), while that of nonalcoholic fatty liver disease (NAFLD) progressively decreased in the same order (33.3%, 6.6%, and 1.8%, respectively). HCC, hepatocellular carcinoma; NAFLD, nonalcoholic fatty liver disease.
Figure 3 The cause of acute hepatitis. The main etiologies of acute hepatitis were hepatitis A virus (HAV; 44.3%), toxic hepatitis (32.4%), and HCV (6.4%); HAV and hepatitis C virus (HCV) were observed together in two patients, and HAV and hepatitis E virus (HEV) were observed together in six. HAV, hepatitis A virus; HBV, hepatitis B virus; EBV, Epstein-Barr virus.
Figure 4 Classification of chronic liver disease according to viral etiology. Among the causes of chronic viral hepatitis, HBV/HCV was the cause in 82.0%/17.5%, while in cirrhosis and HCC, HBV/HCV was the cause in 83.7%/15.5% and 74.9%/24.1% of cases, respectively. HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus.
Type and cause of liver disease in Korea: single-center experience, 2005-2010
Diagnosis (male %, mean age, years) N (%) Cause N (%)
Acute hepatitis (50.8%, 40.1) 528 (8.4) Viral 309 (58.5)
Toxic 171 (32.4)
Cryptogenic 48 (9.1)
Chronic hepatitis (62.5%, 47.1) 3,957 (62.7) Viral 2,027 (51.2)
 HBV (82.0%) 1,663
 HCV (17.5%) 355
 HBV+HCV (0.4%) 9
Alcoholic 513 (13.0)
NAFLD 1,318 (33.3)
Autoimmune 77 (1.9)
Willson disease 5 (0.0)
Others 17 (0.4)
Liver cirrhosis (64.3%, 56.6) 767 (12.2) Viral 563 (73.4)
 HBV (83.7%) 471
 HCV (15.5%) 87
 HBV+HCV (0.9%) 5
Alcoholic 139 (18.1)
Cryptogenic 50 (6.6)
Autoimmune 7 (0.9)
Budd-Chiari syndrome 8 (1.0)
Primary liver cancer 509 (8.1)
 HCC (74.8%, 62.3) 484 (7.7) Viral 419 (86.6)
 HBV (74.9%) 314
 HCV (24.1%) 101
 HBV+HCV (1.0%) 4
Alcoholic 56 (11.6)
Cryptogenic 9 (1.8)
 Cholangiocarcinoma (56.0%, 64.0) 25 (0.4)
Metastatic liver cancer (55.6%, 61.9) 36 (0.6)
Other benign mass (37.6%, 50.5) 510 (8.1) Hemangioma 257 (50.4)
FNH, AML 15 (2.9)
Cyst 166 (32.5)
Pyogenic abscess 30 (5.9)
Eosionophilic Abscess 24 (4.7)
Others* 18 (3.5)
Total (60.7%, 49.3) 6,307 (100) 6,307 (100)
Classification (number, %) Etiology N (%)
Malignant tumor (545, 52.6) HCC 484 (88.8)
Cholangiocarcinoma 25 (4.6)
Metastasis 36 (6.6)
Benign tumor (492, 47.4)
 Neoplastic tumor (272, 26.2) Hemangioma 257 (52.2)
Others (FNH, AML) 15 (3.0)
 Inflammatory mass (220, 21.2) Cyst 166 (33.7)
Pyogenic abscess 30 (6.1)
Eosinophilic abscess 24 (4.9)
Total 1,037 (100)
Table 1. Classification of patients according to the diagnosis and cause of liver disease (2005-2010)

Others: hepatic calcification (n=16), inflammatory psedotumor (n=1), peliosis hepatitis (n=1).

NAFLD, nonalcoholic fatty liver disease; HCC, hepatocellular carcinoma; FNH, focal nodular hyperplasia; AML, angiomyolipoma; HBV, hepatitis B virus; HCV, hepatitis C virus; HBV+HCV, hepatitis B and C virus coinfection.

Table 2. Classification of patients according to the liver tumor

HCC, hepatocellular carcinoma; FNH, focal nodular hyperplasia; AML, angiomyolipoma.